- Current report filing (8-K)
June 07 2010 - 9:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of Earliest Event Reported):
June 4, 2010
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification
No.)
|
incorporation)
|
|
|
|
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices)
(425) 354-5038
Registrants telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
1.01. Entry into a Material Definitive
Agreement.
On June 4, 2010, AVI
BioPharma, Inc. (the Company), entered into a new contract with the U.S.
Defense Threat Reduction Agency (DTRA)
to advance the development of AVI-7100, which was previously designated
AVI-7367 and which has been renumbered by AVI, as a medical countermeasure
against the pandemic H1N1 influenza virus (swine flu) in cooperation with the
Transformational Medical Technologies program (TMT) of the U.S. Department of
Defense. The contract provides for funding of up to $18 million to advance the
development of AVI-7100, including studies enabling an Investigational New Drug
(IND) application with the U.S. Food and Drug Administration, the study of an intranasal
delivery formulation, and the funding of a Phase 1 clinical trial to obtain
human safety data to support potential use under an Emergency Use
Authorization.
AVI-7100 is the Companys
lead RNA-based influenza therapeutic candidate using AVIs proprietary PMO
plus
chemistry. AVI recently secured
additional funding of up to approximately $4.0 million under an amendment to a
separate earlier contract with DTRA to support, in cooperation with TMT,
expanded preclinical evaluation of AVI-7100 against H1N1, H5N1 (avian flu), and
drug resistant H1N1 and H3N2 flu strains.
2
SIGNATURES
Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of
Bothell, State of Washington, on June 7, 2010.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/ J. David Boyle II
|
|
|
|
|
|
J. David Boyle II
|
|
|
Interim
President and Chief Executive Officer, and
|
|
|
Senior
Vice President and Chief Financial Officer
|
3
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024